BCL2 and glioblastoma: The GRPR antagonists RC-3095, RC-3049-III, RC-3049-Et inhibited the proliferation of the human glioblastoma cell lines U-87-MG, U-373-MG, and U-118MG (138, 149) and in U-118MG (145); the tumoral expression of VEGF; the expression of PKC-alpha; and the Bcl-2:Bax ratio, indicating a net apoptotic gain.